Management Team

Dr Gisela Mautner 

Chief Executive Officer and Managing Director

MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia), AMCEOI, MAICD

Dr Mautner is an international business leader with significant experience developing and launching new pharmaceutical products, and delivering successful corporate strategies in highly competitive global markets.

After joining Noxopharm in 2019 as Chief Medical Officer, Gisela was appointed to the CEO and Managing Director roles in early 2022. Her focus is on leading the strategy for Noxopharm’s next stage of development, and the creation and out-licensing of drug assets in oncology and inflammatory disease.

In addition to serving on the Noxopharm Board, she is also a Non-Executive Director of Nyrada Inc, a US biotechnology company listed on the ASX, as well as a member of the Board of NFP Australian Ice Racing.

Before joining Noxopharm, Gisela spent more than 30 years in the medical sector, including leadership in global pharmaceutical organisations across multiple continents and therapeutic areas.

Having held senior positions at major companies including MSD (Merck), Bayer and Amgen, in roles encompassing operations, medical and scientific advisory, research and marketing, Gisela brings a deep understanding of the industry to Noxopharm.

Gisela has strong industry networks and served as President, Vice-President and Treasurer of the Australian Pharmaceutical Physicians Association (APPA) for many years, and is currently serving as Past-President. She is also the Australian delegate for the International Federation of Associations of Pharmaceutical Physicians (IFAPP), which connects the pharmaceutical industry globally.

Gisela’s leadership experience is founded on an education at some of the world’s highest-ranking institutions, with an MBA from the Kellogg School of Management at Northwestern University in Chicago, a Master of Public Health from Harvard, a PhD from Ludwig Maximilian University in Munich, and a Doctor of Medicine degree from Technical University in Munich. She is also a Member of the Australian Institute of Company Directors and the CEO Institute.

Read more

Dr Jeanette Bell 

Chief Operating Officer

BMedSc, MScM, PhD

Jeanette has been engaged in the private, public and corporate healthcare sectors for over three decades, including a successful 15-year period at Lilly Pharmaceuticals.

Her extensive management experience in large pharmaceutical companies, from drug development and clinical trials through to drug launches and commercialisation, gives her a deep understanding of the mechanisms required to progress assets through the drug development pipeline to market.

Jeanette has held international leadership positions across Australia, Europe and Asia, and has deep insights into the intricate frameworks required to deliver a strategic vision across multiple regions and stakeholder groups.

Jeanette holds a PhD (Computer Science) from UTS Sydney, a Master of Science Management (UTS) and a Bachelor of Medical Science (UTS), and as well as operations-related qualifications in portfolio management and Six Sigma methodologies.

Read more

Dr John Wilkinson 

Chief Scientific Officer - Oncology

BSc Hons, PhD

John brings over 30 years’ scientific leadership in oncology and virology from biotech, pharmaceutical and research settings in Australia and the UK.

He has managed high-performing teams with a focus on the development of small molecules to target viruses and cancer through preclinical and clinical stages, and has extensive experience in drug development, formulation, regulatory and manufacture. Over the course of his career, John has formed relationships with key players in pharma, academia and clinical research, and has proven success in leading complex projects to bring products through development and into the clinic.

John’s career includes positions with Biotron Ltd, University of NSW, St Vincent’s Centre for Applied Medical Research, Westmead Millennial Institute, Sydney Children’s’ Hospital, Chelsea & Westminster Hospital in London and Wellcome Research Laboratories in the UK.

John holds a PhD in immunology from the University of NSW and a Bachelor of Science from the University of Portsmouth in the UK.

Read more

Dr Olivier Laczka 

Chief Scientific Officer - Inflammation

BSc, MSc, PhD

Olivier is a highly experienced leader in drug development, biopharmaceuticals, biotechnology and diagnostics.

His skillset includes immunoassays, patents, scientific writing and grants, as well as people and project management. Olivier brings to Noxopharm diverse experience in generating both intellectual property and research funding, along with managing effective collaborations with commercial organisations, academic institutions, governments, and private entities at the international level.

Prior to joining the company in 2018, Olivier was a senior research scientist with 3M, PriME Biologics and AEGROS Innovations. He also held various roles in academic institutions such as UTS Sydney, Macquarie University, and the Institute of Microelectronics of Barcelona.

Olivier holds a PhD in Biotechnology from the Autonomous University of Barcelona, a Master of Applied Biotechnology and Microbiology from Ecole Supérieure d’Ingénieur de Luminy in Marseille, and a Bachelor degree in Biology and Environmental Sciences from the Institut Universitaire de Technology in Nantes.

Read more

Shawn Van Boheemen 

Chief Financial Officer

BBus MCom, FCPA, JP

Shawn has 30 years' experience in commercial finance leadership positions across a range of healthcare, biotech, manufacturing, service-based and financial services industries.

His experience includes Australian ASX and ASIC reporting, SEC reporting in the US, compliance and regulatory affairs, audit (internal and external), taxation, business and financial analytics, intellectual property protection, and regulatory and financial reporting both in Australia and the US.

He has worked in senior financial positions for several Australian and multinational organisations, including Covance, Unomedical, M.D. Sass and New York Life Insurance.

Shawn holds a Master of Commerce degree with a major in Accounting (UWS), a Bachelor of Business degree in Accounting and Commercial Law (UWS), and is a Fellow of the Australian Society of Certified Practising Accountants as well as a Justice of the Peace in NSW.

Read more